If you or a loved one took Zantac and developed cancer, you may be entitled to significant compensation. Lawsuits against manufacturers like GSK, Pfizer, Sanofi, and Boehringer Ingelheim allege that Zantac’s active ingredient, ranitidine, contained a cancer-causing chemical, NDMA, and that companies failed to warn consumers. Explore Zantac’s background, its cancer risks, the latest news, and how direct2attorney can help you seek justice.
What Is Zantac?
Zantac, generically known as ranitidine, is a heartburn and acid reflux medication first approved by the FDA in 1983. Developed by Glaxo (now GSK), it became the world’s best-selling drug by 1988, generating over $1 billion annually. Available as a prescription and over-the-counter drug, Zantac was sold by GSK, Pfizer, Sanofi, and Boehringer Ingelheim at various times. It worked by reducing stomach acid but was pulled from the U.S. market in 2020 after tests showed ranitidine could degrade into N-Nitrosodimethylamine (NDMA), a probable carcinogen. Despite its popularity, concerns about its safety lingered for decades, fueling current litigation.
At Direct2Attorney, we believe in your right to justice.
Our legal specialists will review your case thoroughly to identify your options.
We will assess your eligibility and assist you in filing your case, ensuring you feel supported throughout the process.
Zantac’s active ingredient, ranitidine, can break down into NDMA, a chemical classified as a probable human carcinogen by the World Health Organization. A 2019 study by Valisure detected NDMA in Zantac samples, prompting the FDA’s 2020 recall. Studies, including a 2024 analysis, link NDMA exposure to cancers such as bladder, kidney, liver, stomach, esophageal, and pancreatic, with bladder and kidney cancers showing the strongest evidence. Lawsuits allege manufacturers knew or should have known about NDMA risks since the 1980s but concealed them to protect profits, leaving users vulnerable to life-threatening illnesses.
If you’ve experienced health issues due to Zantac, we are here to help you secure the compensation you deserve. Contact Us
Zantac Lawsuit Updates
As of April 2025, Zantac litigation remains active despite major settlements. GSK settled 80,000 lawsuits for $2.2 billion in October 2024, resolving 93% of its U.S. state court cases, and paid $70 million to settle a whistleblower claim by Valisure. Sanofi settled 4,000 claims for $100 million in May 2024, while Pfizer resolved over 10,000 state court cases. Over 70,000 lawsuits continue in Delaware, with trials ongoing against Boehringer Ingelheim, including a recent Illinois retrial for prostate cancer claims and an Oakland, California, case focused on bladder cancer. A Texas trial began this month, and direct2attorney is accepting new cases as statutes of limitations vary.
Lawsuits claim Zantac’s manufacturers hid that ranitidine could form NDMA, a cancer-causing chemical, leading to cancers in users without proper warnings.
Individuals diagnosed with cancers like bladder, kidney, liver, or stomach after taking Zantac, or their families, may qualify with proof of use and diagnosis.
Zantac is linked to cancers including bladder, kidney, liver, stomach, esophageal, and pancreatic due to NDMA, a probable carcinogen formed from ranitidine.
Compensation may cover medical expenses, pain and suffering, lost wages, and punitive damages, with payouts potentially ranging from $100,000 to millions.
Statutes of limitations vary by state, typically one to three years from diagnosis or discovery. Consult an attorney to confirm your deadline.
GSK, Sanofi, and Pfizer settled thousands of cases, but over 70,000 lawsuits remain in Delaware. Trials continue, with new cases filed nationwide.
Contact direct2attorney’s mass tort experts for Redsa free consultation to evaluate your claim and guide you through the legal process.
